Home » Biotechnology » Neuro Organoids Market

Neuro Organoids Market By Product Type (Ready-to-Use Neural Organoid Products, Personalized Neuro Organoid Models); By Source (Induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), Adult Stem Cells); By Application (Drug Discovery & Development, Disease Modeling, Neurotoxicity Testing, Personalized Medicine & Precision Neurology); By End-Use (Pharmaceutical & Biotechnology Companies, CROs / CDMOs, Academic & Research Institutions) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

Market Overview

The Neuro Organoids market size was valued at USD 39.70 million in 2018, increased to USD 85.51 million in 2024, and is anticipated to reach USD 420.35 million by 2032, at a CAGR of 20.54% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Neuro Organoids Market Size 2024	USD 85.51 million
Neuro Organoids Market, CAGR	20.54%
Neuro Organoids Market Size 2032	USD 420.35 million

The Neuro Organoids market is led by prominent players such as Thermo Fisher Scientific Inc., Merck KGaA, Corning Incorporated, STEMCELL Technologies, and HUB Organoids, each contributing significantly through innovative product offerings and robust R&D capabilities. These companies maintain a strong presence across key application areas, including drug discovery, disease modeling, and personalized neurology. North America emerged as the leading region in 2024, capturing 43.3% of the global market share, driven by advanced research infrastructure, high funding levels, and early adoption of neuro organoid technologies. Europe followed with a 28.5% share, supported by progressive research policies and academic collaboration. These regions are the primary hubs for strategic partnerships, clinical research, and commercialization, allowing key players to expand their global footprint and maintain competitive advantage.

Market Insights

The Neuro Organoids market was valued at USD 85.51 million in 2024 and is projected to reach USD 420.35 million by 2032, growing at a CAGR of 20.54% during the forecast period.
Market growth is driven by increasing demand for advanced in vitro neurological models in drug discovery, personalized medicine, and disease modeling, along with rising prevalence of neurodegenerative disorders.
Key trends include the integration of AI with high-content screening, growing applications in neurotoxicity testing, and advancements in 3D culture and stem cell technologies enhancing scalability and precision.
Leading players such as Thermo Fisher Scientific Inc., Merck KGaA, and STEMCELL Technologies dominate through innovation, strategic partnerships, and diverse product offerings, although the market faces restraints such as high cost, lack of standardization, and ethical concerns.
Regionally, North America led with 43.3% of the market in 2024, followed by Europe at 28.5% and Asia Pacific at 20.2%, while Ready-to-Use Neural Organoid Products held a 58% segment share.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Segmentation Analysis:

By Product Type

The Neuro Organoids market is segmented into Ready-to-Use Neural Organoid Products and Personalized Neuro Organoid Models. Among these, the Ready-to-Use Neural Organoid Products segment dominated the market in 2024, accounting for over 58% of the total revenue share. The dominance is primarily driven by growing demand for standardized, off-the-shelf organoid solutions in pharmaceutical and biotechnology research. These products significantly reduce lead time and simplify experimental workflows, making them ideal for high-throughput screening applications. Additionally, increased investment in automated organoid platforms further supports the growth of this segment.

For instance, STEMCELL Technologies launched its ready-to-use cerebral organoid kit, which supports over 30 days of neural tissue maturation and has been adopted by over 200 research labs worldwide as of 2023.

By Source:

Based on source, the market is categorized into Induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), and Adult Stem Cells. The Induced Pluripotent Stem Cells (iPSCs) segment held the largest share, contributing to approximately 64% of market revenue in 2024. This dominance is attributed to their ability to generate patient-specific neural tissues, making them highly valuable for personalized medicine and disease modeling. Their non-controversial origin, compared to ESCs, and broader differentiation potential than adult stem cells, further fuel adoption across academic and commercial research.

For instance, FUJIFILM Cellular Dynamics Inc. has produced more than 300 iPSC lines for neural differentiation, which are currently being used in over 40 neurological research programs globally.

By Application:

In terms of application, the market is segmented into Drug Discovery & Development, Disease Modeling, Neurotoxicity Testing, and Personalized Medicine & Precision Neurology. Drug Discovery & Development emerged as the leading application, holding over 45% market share in 2024. This is driven by the rising need for accurate and scalable in vitro brain models that replicate human neural physiology, enhancing preclinical testing efficiency. Neuro organoids provide high biological relevance, reducing reliance on animal models and improving predictive outcomes for central nervous system (CNS) drugs, thereby accelerating pharmaceutical pipelines.

Market Overview

Rising Demand for Advanced Neurological Disease Models

The increasing prevalence of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS is driving the demand for more accurate in vitro models. Neuro organoids, which closely mimic the architecture and functionality of the human brain, offer superior platforms for studying disease progression and drug efficacy. Pharmaceutical and biotech companies are adopting these models to reduce drug development timelines and improve success rates in clinical trials. This growing demand for precise and human-relevant disease models significantly contributes to the market’s rapid expansion.

For instance, Roche utilized patient-derived cortical organoids in collaboration with the Allen Institute to evaluate early-stage Alzheimer’s biomarkers across 150 compound candidates in preclinical screens.

Technological Advancements in Organoid Culture Systems

Technological innovations in stem cell biology, 3D cell culture, and microfluidic systems are fueling the development of more robust and reproducible neuro organoids. Automation and bioprinting have improved scalability and reduced variability, making organoid-based research more accessible and commercially viable. Additionally, advancements in imaging and analytical tools enable deeper insights into organoid behavior and neural network formation. These technological breakthroughs are enhancing product reliability and accelerating the integration of neuro organoids into drug discovery and personalized medicine applications.

For instance, InSphero’s Akura™ Flow microfluidic system allows real-time monitoring of up to 96 brain organoids simultaneously, improving screening throughput by over 70% compared to traditional culture systems.

Increased Investment in Personalized Medicine and Precision Neurology

Growing interest in personalized medicine is promoting the use of patient-specific neuro organoids derived from induced pluripotent stem cells (iPSCs). These models allow researchers to evaluate individual drug responses and develop targeted treatments for neurological conditions. Government initiatives and private funding for precision neurology research are further supporting the adoption of neuro organoids. As healthcare shifts toward customized therapeutic solutions, neuro organoids are gaining traction as a crucial tool in translating genomic insights into personalized treatment strategies.

Key Trends and Opportunities

Expansion of Organoids in Neurotoxicity Screening

There is a growing trend of utilizing neuro organoids in neurotoxicity testing to evaluate the safety of new chemical entities and environmental toxins. Regulatory bodies and research institutions are increasingly promoting alternatives to animal testing, favoring organoid models for their human-specific responses and ethical compliance. This creates significant opportunities for market players to develop validated neurotoxicity assays using organoids, especially in the cosmetics, pharmaceutical, and environmental sectors where regulatory pressures are intensifying.

For instance, Merck KGaA integrated human neural spheroids into its BioReliance® toxicity testing suite in 2023, enabling neurotoxicity evaluations across over 120 compounds in pharmaceutical pipelines.

Integration of Artificial Intelligence and High-Content Screening

The integration of AI and machine learning with high-content imaging systems is transforming neuro organoid research. These technologies enable the automated analysis of complex organoid phenotypes, improving throughput and reproducibility. AI-assisted analytics allow for faster identification of neural abnormalities and drug effects, boosting efficiency in preclinical studies. This trend presents opportunities for tech-bio collaborations and the development of smart, data-driven platforms for next-generation neurological research.

Key Challenges

Standardization and Reproducibility Issues

One of the critical challenges in the neuro organoids market is the lack of standardized protocols for organoid generation and analysis. Variability in stem cell sources, culture conditions, and differentiation methods often leads to inconsistent outcomes, limiting scalability and clinical translation. This hinders regulatory acceptance and slows commercial adoption. Addressing these issues requires the development of harmonized guidelines and validated manufacturing processes to ensure reproducibility across laboratories and end users.

For instance, the NIH Human Biomolecular Atlas Program (HuBMAP) has funded over 35 labs to establish reproducible brain organoid protocols, generating a centralized data repository for reproducibility validation across institutions.

Ethical and Regulatory Hurdles

The use of human-derived stem cells, particularly embryonic stem cells, raises ethical concerns that vary across regions and regulatory bodies. While iPSCs offer a less controversial alternative, navigating the complex regulatory landscape remains a barrier for market expansion. Additionally, the evolving nature of neuro organoids—especially their potential for advanced neural activity—has sparked debates about ethical boundaries in brain research, further complicating approvals and public acceptance.

High Cost of Development and Maintenance

Neuro organoid culture systems require specialized infrastructure, skilled personnel, and expensive reagents, resulting in high operational costs. These factors limit adoption, especially among small- and medium-sized research organizations. Moreover, the need for advanced imaging, data analysis tools, and controlled environments adds to the total cost of ownership. Reducing these costs through technological innovation and economies of scale is essential to broaden market reach and accessibility.

Regional Analysis

North America

North America held the largest share of the Neuro Organoids market, accounting for 43.3% of the global revenue in 2024, with market size rising from USD 17.37 million in 2018 to USD 37.02 million in 2024, and projected to reach USD 182.48 million by 2032 at a robust CAGR of 20.6%. The region’s dominance is driven by advanced research infrastructure, substantial funding in neuroscience, and strong presence of key biotech players. High adoption of patient-specific organoid models and regulatory support for personalized medicine continue to fuel market growth across the U.S. and Canada.

For instance, Thermo Fisher Scientific invested USD 65 million in 2023 to expand its cell culture and organoid production facility in Grand Island, NY, which now supports over 500 neuro organoid research programs across North America

Europe

Europe represented the second-largest regional market in 2024, with a share of 28.5%, growing from USD 11.76 million in 2018 to USD 24.47 million in 2024, and anticipated to reach USD 113.54 million by 2032, expanding at a CAGR of 19.7%. Growth in the region is supported by government-backed initiatives in stem cell research and an expanding pharmaceutical pipeline. Countries like Germany, the U.K., and France are investing heavily in advanced neurological studies, while ethical regulations around stem cell usage remain streamlined, encouraging greater adoption of neuro organoid platforms in academic and clinical research.

For instance, the UK Dementia Research Institute partnered with HUB Organoids in 2023 to develop cerebral organoids for early-onset dementia, with over 2,000 patient-derived organoids created under the initiative.

Asia Pacific

Asia Pacific emerged as the fastest-growing regional market with a CAGR of 22.5%, growing from USD 7.40 million in 2018 to USD 17.31 million in 2024, and forecast to reach USD 96.73 million by 2032. The region accounted for 20.2% of the global market share in 2024. Rapid advancements in stem cell research, growing biotechnology sectors in China, Japan, and South Korea, and increasing government funding are driving regional growth. Moreover, expanding clinical trial activity and increasing collaboration between academia and industry are accelerating the adoption of neuro organoid technologies across Asia Pacific.

Latin America

Latin America captured a modest 4.3% market share in 2024, with market size growing from USD 1.72 million in 2018 to USD 3.67 million in 2024, and projected to reach USD 15.76 million by 2032, at a CAGR of 18.5%. Brazil and Mexico are key contributors, driven by improving research capabilities and increased academic interest in neurological disorders. Although the market is in its early stages, the rising burden of brain-related illnesses and supportive government initiatives for biomedical research are creating a favorable environment for the gradual expansion of neuro organoid technologies in the region.

Middle East

The Middle East accounted for 2.2% of the global Neuro Organoids market in 2024, increasing from USD 0.96 million in 2018 to USD 1.87 million in 2024, and expected to reach USD 7.49 million by 2032, growing at a CAGR of 17.5%. Growth is largely concentrated in Gulf Cooperation Council (GCC) countries, where investments in medical research infrastructure are rising. Interest in personalized healthcare and precision medicine is expanding slowly but steadily, supported by collaborations with international institutions. However, the region still faces limitations in skilled personnel and laboratory infrastructure needed for large-scale neuro organoid research.

Africa

Africa held the smallest market share of 1.4% in 2024, with its Neuro Organoids market expanding from USD 0.48 million in 2018 to USD 1.18 million in 2024, and projected to reach USD 4.34 million by 2032, at a CAGR of 16.2%. The market remains underdeveloped due to limited research infrastructure and funding. Nonetheless, growing interest in neurological disorders and early initiatives in biomedical innovation in countries such as South Africa and Nigeria are beginning to lay the groundwork for future growth. International partnerships and training programs will be crucial in supporting wider adoption of organoid technologies in Africa.

Market Segmentations:

By Product Type:

Ready-to-Use Neural Organoid Products
Personalized Neuro Organoid Models

By Source:

Induced Pluripotent Stem Cells (iPSCs)
Embryonic Stem Cells (ESCs)
Adult Stem Cells

By Application:

Drug Discovery & Development
Disease Modeling
Neurotoxicity Testing
Personalized Medicine & Precision Neurology

By End Use:

Pharmaceutical & Biotechnology Companies
CROs / CDMOs
Academic & Research Institutions

By Geography:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Competitive Landscape

The competitive landscape of the Neuro Organoids market is characterized by the presence of established biotechnology and life sciences companies alongside emerging players specializing in organoid technologies. Key market participants such as Thermo Fisher Scientific Inc., Merck KGaA, and Corning Incorporated leverage their extensive research capabilities, broad product portfolios, and global distribution networks to maintain a competitive edge. Specialized firms like STEMCELL Technologies, HUB Organoids, and InSphero focus on innovation in 3D cell culture and patient-specific organoid models, catering to niche research needs. Strategic collaborations, product launches, and investments in advanced culture systems are common strategies adopted to strengthen market position. Companies are also increasingly integrating artificial intelligence and automation into organoid development processes to enhance scalability and reproducibility. The market remains moderately fragmented, with competition driven by technological innovation, customization capabilities, and responsiveness to evolving demands in drug discovery, disease modeling, and personalized medicine. As adoption grows, competitive intensity is expected to increase further.

For instance, Corning Incorporated expanded its 3D cell culture business by supplying over 1 million Matrigel® matrix units globally in 2023, supporting more than 350 neuro organoid research publications

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Thermo Fisher Scientific Inc.
Corning Incorporated
Merck KGaA
STEMCELL Technologies
HUB Organoids
InSphero
BioIVT
ACROBiosystems
Bio‑Techne
Qkine Ltd.
AMSBIO

Recent Developments

In April 2025, a study using assembloid models built from human pluripotent stem cells demonstrated the integration of somatosensory, spinal, thalamic, and cortical organoids, enabling the modeling of the ascending neural sensory pathway. While not directly a Thermo Fisher Scientific product, the company is a significant supplier of reagents and tools used in this type of research and was recognized as a key market player in late 2024.
In August 2024, BioIVT (US) acquired ZenBio (US), a key player in advanced cell products and services. The two companies will jointly provide an expanded range of skin-based expertise, primary cell and exosome isolation, and blood products for the pharmaceutical and cosmetics industries.
In July 2024, Merck KGaA (Germany) launched commercial production for its first GMP-compliant cell culture media (CCM) manufacturing line.
In June 2024, Corning Incorporated (US) collaborated with the National Institute for Bioprocessing Research and Training (NIBRT) (Ireland). NIBRT is the center for biopharmaceutical manufacturing research and training. With this collaboration, Corning will place one of its Ascent Fixed Bed Bioreactor (FBR) Systems at NIBRT’s Advanced Therapies building in Dublin, Ireland. This collaboration enhances Corning’s access to the European life sciences market and the rapidly expanding Irish market.
In May 2024, InSphero (Switzerland) collaborated with Genome Biologics (Germany). This partnership will give InSphero exclusive global rights to commercialize Genome Biologics’ groundbreaking 3D Cardiac Organoid Platform. This platform leads in cardiac disease research and provides precise, scalable, and disease-specific organoid models essential for developing new therapeutics.

Market Concentration & Characteristics

The Neuro Organoids Market exhibits a moderate to high level of concentration, with a few global players holding a significant share of the market revenue. It is characterized by strong research-driven innovation, specialized product offerings, and a focus on custom solutions tailored for drug discovery, disease modeling, and neurotoxicity testing. The market features a blend of large life sciences corporations and niche biotechnology firms, where leading companies differentiate themselves through proprietary technologies, stem cell expertise, and strategic partnerships with academic institutions. It remains highly technology-intensive, requiring specialized infrastructure, advanced 3D culture capabilities, and skilled personnel. Entry barriers are substantial due to high development costs and the complexity of standardizing reproducible organoid systems. Regulatory compliance and ethical considerations, particularly around stem cell sourcing, further define the competitive environment. It continues to evolve rapidly, influenced by increasing demand for human-relevant preclinical models and precision medicine. Regional growth depends on funding availability, infrastructure maturity, and regulatory frameworks supporting advanced biological research.

Report Coverage

The research report offers an in-depth analysis based on Product Type, Source, Application, End Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Neuro Organoids market is expected to witness strong growth driven by rising demand for personalized neurology solutions.
Increasing application of neuro organoids in drug discovery and toxicity testing will support market expansion.
Advancements in stem cell and 3D culture technologies will improve organoid accuracy and scalability.
Integration of AI and automation will enhance data analysis and throughput in neuro organoid research.
Regulatory support for alternatives to animal testing will increase adoption of organoid models.
North America and Europe will continue to dominate the market due to advanced research infrastructure.
Asia Pacific is projected to grow at the fastest rate, supported by increasing investments in biotech research.
Collaboration between biotech firms and academic institutions will accelerate innovation in organoid development.
Ethical sourcing and reproducibility challenges will remain key concerns for broader adoption.
Expansion into neurodegenerative disease modeling will open new avenues for clinical and commercial applications.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: NEURO ORGANOIDS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Product

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Product Type & Application Revenue

CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Neuro Organoids Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Neuro Organoids Market Export Revenue By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Neuro Organoids Market: Company Market Share

7.2. Global Neuro Organoids Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: NEURO ORGANOIDS MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS

8.1. Neuro Organoids Market Overview by Product Type Segment

8.1.1. Neuro Organoids Market Revenue Share By Product Type

8.2. Ready-to-Use Neural Organoid Products

8.3. Personalized Neuro Organoid Models

CHAPTER NO. 9: NEURO ORGANOIDS MARKET – BY SOURCE SEGMENT ANALYSIS

9.1. Neuro Organoids Market Overview by Source Segment

9.1.1. Neuro Organoids Market Revenue Share By Source

9.2. Induced Pluripotent Stem Cells (iPSCs)

9.3. Embryonic Stem Cells (ESCs)

9.4. Adult Stem Cells

CHAPTER NO. 10: NEURO ORGANOIDS MARKET – BY APPLICATION SEGMENT ANALYSIS

10.1. Neuro Organoids Market Overview by Application Segment

10.1.1. Neuro Organoids Market Revenue Share By Application

10.2. Drug Discovery & Development

10.3. Disease Modeling

10.4. Neurotoxicity Testing

10.5. Personalized Medicine & Precision Neurology

CHAPTER NO. 11: NEURO ORGANOIDS MARKET – BY END USE SEGMENT ANALYSIS

11.1. Neuro Organoids Market Overview by End Use Segment

11.1.1. Neuro Organoids Market Revenue Share By End Use

11.2. Pharmaceutical & Biotechnology Companies

11.3. CROs / CDMOs

11.4. Academic & Research Institutions

CHAPTER NO. 12: NEURO ORGANOIDS MARKET – REGIONAL ANALYSIS

12.1. Neuro Organoids Market Overview by Region Segment

12.1.1. Global Neuro Organoids Market Revenue Share By Region

12.1.2. Regions

12.1.3. Global Neuro Organoids Market Revenue By Region

12.1.4. Product Type

12.1.5. Global Neuro Organoids Market Revenue By Product Type

12.1.6. Source

12.1.7. Global Neuro Organoids Market Revenue By Source

12.1.8. Application

12.1.9. Global Neuro Organoids Market Revenue By Application

12.1.10. End Use

12.1.11. Global Neuro Organoids Market Revenue By End Use

CHAPTER NO. 13: NORTH AMERICA NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

13.1. North America Neuro Organoids Market Overview by Country Segment

13.1.1. North America Neuro Organoids Market Revenue Share By Region

13.2. North America

13.2.1. North America Neuro Organoids Market Revenue By Country

13.2.2. Product Type

13.2.3. North America Neuro Organoids Market Revenue By Product Type

13.2.4. Source

13.2.5. North America Neuro Organoids Market Revenue By Source

13.2.6. Application

13.2.7. North America Neuro Organoids Market Revenue By Application

13.2.8. End Use

13.2.9. North America Neuro Organoids Market Revenue By End Use

13.3. U.S.

13.4. Canada

13.5. Mexico

CHAPTER NO. 14: EUROPE NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

14.1. Europe Neuro Organoids Market Overview by Country Segment

14.1.1. Europe Neuro Organoids Market Revenue Share By Region

14.2. Europe

14.2.1. Europe Neuro Organoids Market Revenue By Country

14.2.2. Product Type

14.2.3. Europe Neuro Organoids Market Revenue By Product Type

14.2.4. Source

14.2.5. Europe Neuro Organoids Market Revenue By Source

14.2.6. Application

14.2.7. Europe Neuro Organoids Market Revenue By Application

14.2.8. End Use

14.2.9. Europe Neuro Organoids Market Revenue By End Use

14.3. UK

14.4. France

14.5. Germany

14.6. Italy

14.7. Spain

14.8. Russia

14.9. Rest of Europe

CHAPTER NO. 15: ASIA PACIFIC NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

15.1. Asia Pacific Neuro Organoids Market Overview by Country Segment

15.1.1. Asia Pacific Neuro Organoids Market Revenue Share By Region

15.2. Asia Pacific

15.2.1. Asia Pacific Neuro Organoids Market Revenue By Country

15.2.2. Product Type

15.2.3. Asia Pacific Neuro Organoids Market Revenue By Product Type

15.2.4. Source

15.2.5. Asia Pacific Neuro Organoids Market Revenue By Source

15.2.6. Application

15.2.7. Asia Pacific Neuro Organoids Market Revenue By Application

15.2.8. End Use

15.2.9. Asia Pacific Neuro Organoids Market Revenue By End Use

15.3. China

15.4. Japan

15.5. South Korea

15.6. India

15.7. Australia

15.8. Southeast Asia

15.9. Rest of Asia Pacific

CHAPTER NO. 16: LATIN AMERICA NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

16.1. Latin America Neuro Organoids Market Overview by Country Segment

16.1.1. Latin America Neuro Organoids Market Revenue Share By Region

16.2. Latin America

16.2.1. Latin America Neuro Organoids Market Revenue By Country

16.2.2. Product Type

16.2.3. Latin America Neuro Organoids Market Revenue By Product Type

16.2.4. Source

16.2.5. Latin America Neuro Organoids Market Revenue By Source

16.2.6. Application

16.2.7. Latin America Neuro Organoids Market Revenue By Application

16.2.8. End Use

16.2.9. Latin America Neuro Organoids Market Revenue By End Use

16.3. Brazil

16.4. Argentina

16.5. Rest of Latin America

CHAPTER NO. 17: MIDDLE EAST NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

17.1. Middle East Neuro Organoids Market Overview by Country Segment

17.1.1. Middle East Neuro Organoids Market Revenue Share By Region

17.2. Middle East

17.2.1. Middle East Neuro Organoids Market Revenue By Country

17.2.2. Product Type

17.2.3. Middle East Neuro Organoids Market Revenue By Product Type

17.2.4. Source

17.2.5. Middle East Neuro Organoids Market Revenue By Source

17.2.6. Application

17.2.7. Middle East Neuro Organoids Market Revenue By Application

17.2.8. End Use

17.2.9. Middle East Neuro Organoids Market Revenue By End Use

17.3. GCC Countries

17.4. Israel

17.5. Turkey

17.6. Rest of Middle East

CHAPTER NO. 18: AFRICA NEURO ORGANOIDS MARKET – COUNTRY ANALYSIS

18.1. Africa Neuro Organoids Market Overview by Country Segment

18.1.1. Africa Neuro Organoids Market Revenue Share By Region

18.2. Africa

18.2.1. Africa Neuro Organoids Market Revenue By Country

18.2.2. Product Type

18.2.3. Africa Neuro Organoids Market Revenue By Product Type

18.2.4. Source

18.2.5. Africa Neuro Organoids Market Revenue By Source

18.2.6. Application

18.2.7. Africa Neuro Organoids Market Revenue By Application

18.2.8. End Use

18.2.9. Africa Neuro Organoids Market Revenue By End Use

18.3. South Africa

18.4. Egypt

18.5. Rest of Africa

CHAPTER NO. 19: COMPANY PROFILES

19.1. Thermo Fisher Scientific Inc.

19.1.1. Company Overview

19.1.2. Product Portfolio

19.1.3. Financial Overview

19.1.4. Recent Developments

19.1.5. Growth Strategy

19.1.6. SWOT Analysis

19.2. Corning Incorporated

19.3. Merck KGaA

19.4. STEMCELL Technologies

19.5. HUB Organoids

19.6. InSphero

19.7. BioIVT

19.8. ACROBiosystems

19.9. Bio‑Techne

19.10. Qkine Ltd.

19.11. AMSBIO

Frequently Asked Questions

What is the current size of the Neuro Organoids Market?

The Neuro Organoids Market was valued at USD 85.51 million in 2024 and is projected to reach USD 420.35 million by 2032, growing at a CAGR of 20.54% during the forecast period.

What are the key segments within the Neuro Organoids Market?

Key segments in the Neuro Organoids Market include Product Type (Ready-to-Use Neural Organoid Products, Personalized Neuro Organoid Models), Source (iPSCs, ESCs, Adult Stem Cells), Application (Drug Discovery & Development, Disease Modeling, Neurotoxicity Testing, Personalized Medicine & Precision Neurology), End Use (Pharmaceutical & Biotechnology Companies, CROs/CDMOs, Academic & Research Institutions), and Geography.

Who are the major players in the Neuro Organoids Market?

Major players in the Neuro Organoids Market include Thermo Fisher Scientific Inc., Corning Incorporated, Merck KGaA, STEMCELL Technologies, HUB Organoids, InSphero, BioIVT, ACROBiosystems, Bio Techne, Qkine Ltd., and AMSBIO.

What are the market drivers in the Neuro Organoids Market?

The Neuro Organoids Market is driven by rising demand for advanced neurological disease models, increasing investments in personalized medicine and precision neurology, and continuous technological advancements in stem cell culture and 3D bioprinting systems.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –